Q-omics provides the consensus-scored PDCL3P5 profile across patient tissues and cancer cell-line models. PDCL3P5 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PDCL3P5 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, PDCL3P5 RNA expression shows 17,244 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KICH, and UVM as cancer lineages where PDCL3P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDCL3P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDCL3P5 survival associations across molecular data types. PDCL3P5 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDCL3P5 RNA expression–survival associations across cancer types. High PDCL3P5 expression shows unfavorable associations in KIRP, ACC, LGG and UVM, but favorable associations in LUAD and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PDCL3P5 RNA expression.
This table summarizes PDCL3P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for PDCL3P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDCL3P5 shows lower tumor expression in KICH and BRCA and higher tumor expression in STAD, HNSC, KIRC and COAD. The KICH box plot shows higher PDCL3P5 RNA expression in normal versus tumor tissue (log2 FC = −0.411, t-test p < 0.001).
This table shows molecular features associated with PDCL3P5 in patient tissues and cancer cell lines. In patient samples, PDCL3P5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
